Related Experiment Videos

Hypoglycaemic brain damage: effect of a dihydropyridine calcium channel antagonist in rats

R N Auer1, L G Anderson

  • 1Department of Pathology, University of Calgary, Alberta, Canada.

Diabetologia
|February 1, 1996
PubMed

Insights

Nimodipine worsened brain damage and increased mortality in rats experiencing profound hypoglycemia. This contrasts with nimodipine's known benefits in cases of brain ischemia.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pathophysiology

Background:

  • Hypoglycemic brain damage involves neuronal necrosis due to excitatory amino acid release.
  • Activation of neuronal excitatory amino acid receptors opens calcium channels, contributing to neuronal injury.

Purpose of the Study:

  • To evaluate the efficacy of nimodipine, a dihydropyridine calcium channel blocker, in mitigating hypoglycemic brain damage.
  • To investigate the effects of nimodipine on neuronal survival during severe hypoglycemia.

Main Methods:

  • Sixty-four rats were administered varying doses of nimodipine (high-dose and low-dose) or control solutions (vehicle or saline).
  • Nimodipine administration involved an initial bolus at electroencephalogram (EEG) slowing, followed by continuous intravenous infusion.
  • Brain damage was assessed one week post-recovery by quantifying neuronal necrosis in specific brain regions.

Main Results:

  • Both high- and low-dose nimodipine treatments resulted in increased mortality rates compared to control groups.
  • Nimodipine administration exacerbated neuronal necrosis in the hippocampus, caudate nucleus, and cerebral cortex.
  • The detrimental effects of nimodipine were observed in profound hypoglycemia, characterized by a flat EEG.

Conclusions:

  • Nimodipine blockade of voltage-sensitive calcium channels is ineffective and harmful in treating hypoglycemic brain damage.
  • The findings in profound hypoglycemia contrast sharply with the previously observed beneficial effects of nimodipine in brain ischemia.
  • These results suggest that nimodipine should not be used in clinical scenarios involving severe hypoglycemia-induced brain injury.

Related Concept Videos